State of New Jersey Common Pension Fund D Invests $1.92 Million in Hims & Hers Health, Inc. (NYSE:HIMS)

State of New Jersey Common Pension Fund D acquired a new stake in Hims & Hers Health, Inc. (NYSE:HIMS) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 94,987 shares of the company’s stock, valued at approximately $1,918,000.

A number of other institutional investors have also recently added to or reduced their stakes in HIMS. Nisa Investment Advisors LLC lifted its position in shares of Hims & Hers Health by 679.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock valued at $37,000 after acquiring an additional 1,603 shares during the period. Quest Partners LLC increased its stake in Hims & Hers Health by 5,944.1% in the 2nd quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock valued at $72,000 after purchasing an additional 3,507 shares in the last quarter. Van ECK Associates Corp acquired a new position in Hims & Hers Health during the second quarter worth $111,000. Belpointe Asset Management LLC boosted its position in Hims & Hers Health by 10.0% during the fourth quarter. Belpointe Asset Management LLC now owns 13,238 shares of the company’s stock worth $118,000 after purchasing an additional 1,205 shares in the last quarter. Finally, Daiwa Securities Group Inc. acquired a new stake in Hims & Hers Health in the second quarter valued at $142,000. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Price Performance

NYSE HIMS opened at $16.30 on Friday. The company has a market cap of $3.50 billion, a P/E ratio of -1,630.00 and a beta of 1.05. Hims & Hers Health, Inc. has a 12 month low of $5.65 and a 12 month high of $25.74. The company has a 50-day moving average of $17.35 and a 200-day moving average of $17.05.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, August 5th. The company reported $0.06 EPS for the quarter, topping the consensus estimate of $0.04 by $0.02. The firm had revenue of $315.65 million during the quarter, compared to analyst estimates of $302.43 million. Hims & Hers Health had a net margin of 1.70% and a return on equity of 5.25%. Hims & Hers Health’s revenue for the quarter was up 51.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.03) earnings per share. As a group, equities research analysts anticipate that Hims & Hers Health, Inc. will post 0.22 EPS for the current year.

Insider Buying and Selling at Hims & Hers Health

In other news, insider Soleil Boughton sold 2,335 shares of the firm’s stock in a transaction dated Tuesday, July 9th. The stock was sold at an average price of $20.28, for a total value of $47,353.80. Following the transaction, the insider now directly owns 169,144 shares in the company, valued at approximately $3,430,240.32. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, COO Melissa Baird sold 11,749 shares of the company’s stock in a transaction on Wednesday, September 4th. The shares were sold at an average price of $14.65, for a total transaction of $172,122.85. Following the completion of the sale, the chief operating officer now directly owns 585,800 shares of the company’s stock, valued at approximately $8,581,970. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Soleil Boughton sold 2,335 shares of the firm’s stock in a transaction dated Tuesday, July 9th. The shares were sold at an average price of $20.28, for a total value of $47,353.80. Following the completion of the transaction, the insider now directly owns 169,144 shares in the company, valued at $3,430,240.32. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 701,904 shares of company stock valued at $12,349,805. Company insiders own 17.71% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently issued reports on the company. Piper Sandler reaffirmed a “neutral” rating and set a $18.00 price target on shares of Hims & Hers Health in a research note on Tuesday, August 6th. Jefferies Financial Group upped their price target on shares of Hims & Hers Health from $14.00 to $23.00 and gave the company a “hold” rating in a report on Thursday, June 27th. Imperial Capital cut shares of Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research note on Friday, August 9th. Deutsche Bank Aktiengesellschaft upped their target price on Hims & Hers Health from $16.00 to $23.00 and gave the company a “hold” rating in a research note on Wednesday, August 7th. Finally, Needham & Company LLC initiated coverage on Hims & Hers Health in a research report on Thursday, August 22nd. They set a “buy” rating and a $24.00 price target for the company. Eight investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $19.86.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.